AL
ICPT

Airain Ltd’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Airain Ltd’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$560K Buy
+4,629
New +$536K 0.02% 515

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Airain Ltd's ICPT Position: Q2 2017 in Review

Airain Ltd opened a new position in Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2017: 4,629 shares worth $560K. The stake represents 0.02% of the portfolio and ranks #515 among its holdings.

167 funds tracked by Wall St. Rank hold ICPT as of Q2 2017.

  • Airain Ltd held 4,629 shares of Intercept Pharmaceuticals, Inc. worth $560K as of Q2 2017.
  • Intercept Pharmaceuticals, Inc. was a new Airain Ltd position in Q2 2017.
  • Intercept Pharmaceuticals, Inc. made up 0.02% of Airain Ltd's portfolio in Q2 2017, its #515 holding.
  • 167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.